Cart
sales@molnova.com
FT-1518
CAS No. 1313026-58-2
FT-1518( —— )
Catalog No. M32928 CAS No. 1313026-58-2
FT-1518 is an orally available, selective and potent mTORC1 and mTORC2 inhibitor with anticancer and antitumor activity for cancer research.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 61 | In Stock |
|
| 5MG | 101 | In Stock |
|
| 10MG | 163 | In Stock |
|
| 25MG | 330 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameFT-1518
-
NoteResearch use only, not for human use.
-
Brief DescriptionFT-1518 is an orally available, selective and potent mTORC1 and mTORC2 inhibitor with anticancer and antitumor activity for cancer research.
-
DescriptionFT-1518 is a new generation selective, potent and oral bioavailable mTORC1 and mTORC2 inhibitor, and exhibits antitumor activity.
-
In VitroFT-1518 is a new generation selective, potent and oral bioavailable mTORC1 and mTORC2 inhibitor, and exhibits antitumor activity. FT-1518 displays significant growth inhibitory activity against a large panel of hematologic and solid tumor cell lines with most activities falling into low nanomolar range. FT-1518 cuases potent inhibition of the mTOR pathway biomarkers (mTORC 1 & 2 biomarkers [pAkt(S473) and pS6(S240/244) or p70 S6K), no inhibition of PI3K biomarker [pAkt(T308)] in cells.
-
In VivoFT-1518 exhibits dose-dependent and higher tumor growth inhibition (TGI) in multiple solid tumor xenografts.
-
Synonyms——
-
PathwayPI3K/Akt/mTOR signaling
-
TargetmTOR
-
RecptormTOR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1313026-58-2
-
Formula Weight394.47
-
Molecular FormulaC20H26N8O
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 5 mg/mL (12.68 mM; Ultrasonic (<60°C)
-
SMILESN=1C=C(N=CC1N)C2=NC(=NC3=C2N=CN3C(CC)CC)N4CC5OC(C4)CC5
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Alain C. Mita, et al. Abstract 137: FT-1518, a new generation selective and potent mTORC1 and mTORC2 inhibitor: an in vitro and in vivo profile. Cancer Res 2017;77(13 Suppl).
molnova catalog
related products
-
Seco Rapamycin sodiu...
Seco-rapamycin is the first in vivo open-ring metabolite of rapamycin that does not affect mTOR.
-
XL413 hydrochloride
XL-413 is an orally bioavailable cell division cycle 7 homolog (CDC7) kinase inhibitor with potential antineoplastic activity.
-
NSC781406
NSC781406 is a highly effective inhibitor of PI3K and mTOR (IC50: 2 nM for PI3Kα).
